CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions

Despite recent therapeutic advances, the prognosis of multiple myeloma (MM) patients remains poor. Thus, new strategies to improve outcomes are imperative. Chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape of B-cell malignancies, providing a potentially curative opti...

Full description

Bibliographic Details
Main Authors: Luis Gerardo Rodríguez-Lobato, Maya Ganzetti, Carlos Fernández de Larrea, Michael Hudecek, Hermann Einsele, Sophia Danhof
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Oncology
Subjects:
multiple myeloma
immunotherapy
chimeric antigen receptor
B-cell maturation antigen
T-cell
cytokine release syndrome
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01243/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01243/full

Similar Items